Title
CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation

Permalink
https://escholarship.org/uc/item/2j55q5tw

Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 114(32)

ISSN
0027-8424

Authors
Wright, HJ
Hou, J
Xu, B
et al.

Publication Date
2017-08-08

DOI
10.1073/pnas.1703791114

Peer reviewed
CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation

Heather J. Wright,a,b Jue Hou,a,b,c Binzhi Xu,a, Marvin Cortez,a Eric O. Potma,a Bruce J. Trombergb, and Olga V. Razorenova,b,d

aDepartment of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697; bDepartment of Biomedical Engineering, University of California, Irvine, CA 92697; dDepartment of Chemistry, University of California, Irvine, CA 92697

Edited by Joan Massagué, Memorial Sloan-Kettering Cancer Center, New York, NY, and approved June 29, 2017 (received for review March 8, 2017)

Approximately 34% of triple-negative breast cancer (TNBC) patients relapse with local recurrence or metastasis within 5 y of radiation and chemotherapy treatment. There are currently no targeted therapies to treat TNBC. This study offers therapeutic targets for blocking TNBC metastasis: cell-surface antigen CUB-domain containing protein 1 (CDCP1) and proteins in the lipid metabolism pathway. CDCP1 regulates lipid metabolism by reducing cytoplasmic lipid droplet abundance, stimulating fatty acid oxidation and oxidative phosphorylation. This metabolic pathway likely contributes to the energy production required for cell migration and metastasis of TNBC, and represents a potential therapeutic target.


The authors declare no conflict of interest.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1703791114/-/DCSupplemental.

Significance

Approximately 34% of triple-negative breast cancer (TNBC) patients relapse with local recurrence or metastasis within 5 y of radiation and chemotherapy treatment. There are currently no targeted therapies to treat TNBC. This study offers therapeutic targets for blocking TNBC metastasis: cell-surface antigen CUB-domain containing protein 1 (CDCP1) and proteins in the lipid metabolism pathway. CDCP1 regulates lipid metabolism by reducing cytoplasmic lipid droplet abundance, stimulating fatty acid oxidation and oxidative phosphorylation. This metabolic pathway likely contributes to the energy production required for cell migration and metastasis of TNBC, and represents a potential therapeutic target.

Approximately 34% of triple-negative breast cancer (TNBC) patients relapse with local recurrence or metastasis within 5 y of radiation and chemotherapy treatment. There are currently no targeted therapies to treat TNBC. This study offers therapeutic targets for blocking TNBC metastasis: cell-surface antigen CUB-domain containing protein 1 (CDCP1) and proteins in the lipid metabolism pathway. CDCP1 regulates lipid metabolism by reducing cytoplasmic lipid droplet abundance, stimulating fatty acid oxidation and oxidative phosphorylation. This metabolic pathway likely contributes to the energy production required for cell migration and metastasis of TNBC, and represents a potential therapeutic target.

Approximately 34% of triple-negative breast cancer (TNBC) patients relapse with local recurrence or metastasis within 5 y of radiation and chemotherapy treatment. There are currently no targeted therapies to treat TNBC. This study offers therapeutic targets for blocking TNBC metastasis: cell-surface antigen CUB-domain containing protein 1 (CDCP1) and proteins in the lipid metabolism pathway. CDCP1 regulates lipid metabolism by reducing cytoplasmic lipid droplet abundance, stimulating fatty acid oxidation and oxidative phosphorylation. This metabolic pathway likely contributes to the energy production required for cell migration and metastasis of TNBC, and represents a potential therapeutic target.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

1H.J.W. and J.H. contributed equally to this work.

2To whom correspondence should be addressed. Email: olgar@uci.edu.

Approximately 34% of triple-negative breast cancer (TNBC) patients relapse with local recurrence or metastasis within 5 y of radiation and chemotherapy treatment. There are currently no targeted therapies to treat TNBC. This study offers therapeutic targets for blocking TNBC metastasis: cell-surface antigen CUB-domain containing protein 1 (CDCP1) and proteins in the lipid metabolism pathway. CDCP1 regulates lipid metabolism by reducing cytoplasmic lipid droplet abundance, stimulating fatty acid oxidation and oxidative phosphorylation. This metabolic pathway likely contributes to the energy production required for cell migration and metastasis of TNBC, and represents a potential therapeutic target.

Approximately 34% of triple-negative breast cancer (TNBC) patients relapse with local recurrence or metastasis within 5 y of radiation and chemotherapy treatment. There are currently no targeted therapies to treat TNBC. This study offers therapeutic targets for blocking TNBC metastasis: cell-surface antigen CUB-domain containing protein 1 (CDCP1) and proteins in the lipid metabolism pathway. CDCP1 regulates lipid metabolism by reducing cytoplasmic lipid droplet abundance, stimulating fatty acid oxidation and oxidative phosphorylation. This metabolic pathway likely contributes to the energy production required for cell migration and metastasis of TNBC, and represents a potential therapeutic target.

Approximately 34% of triple-negative breast cancer (TNBC) patients relapse with local recurrence or metastasis within 5 y of radiation and chemotherapy treatment. There are currently no targeted therapies to treat TNBC. This study offers therapeutic targets for blocking TNBC metastasis: cell-surface antigen CUB-domain containing protein 1 (CDCP1) and proteins in the lipid metabolism pathway. CDCP1 regulates lipid metabolism by reducing cytoplasmic lipid droplet abundance, stimulating fatty acid oxidation and oxidative phosphorylation. This metabolic pathway likely contributes to the energy production required for cell migration and metastasis of TNBC, and represents a potential therapeutic target.

Approximately 34% of triple-negative breast cancer (TNBC) patients relapse with local recurrence or metastasis within 5 y of radiation and chemotherapy treatment. There are currently no targeted therapies to treat TNBC. This study offers therapeutic targets for blocking TNBC metastasis: cell-surface antigen CUB-domain containing protein 1 (CDCP1) and proteins in the lipid metabolism pathway. CDCP1 regulates lipid metabolism by reducing cytoplasmic lipid droplet abundance, stimulating fatty acid oxidation and oxidative phosphorylation. This metabolic pathway likely contributes to the energy production required for cell migration and metastasis of TNBC, and represents a potential therapeutic target.

Approximately 34% of triple-negative breast cancer (TNBC) patients relapse with local recurrence or metastasis within 5 y of radiation and chemotherapy treatment. There are currently no targeted therapies to treat TNBC. This study offers therapeutic targets for blocking TNBC metastasis: cell-surface antigen CUB-domain containing protein 1 (CDCP1) and proteins in the lipid metabolism pathway. CDCP1 regulates lipid metabolism by reducing cytoplasmic lipid droplet abundance, stimulating fatty acid oxidation and oxidative phosphorylation. This metabolic pathway likely contributes to the energy production required for cell migration and metastasis of TNBC, and represents a potential therapeutic target.

Approximately 34% of triple-negative breast cancer (TNBC) patients relapse with local recurrence or metastasis within 5 y of radiation and chemotherapy treatment. There are currently no targeted therapies to treat TNBC. This study offers therapeutic targets for blocking TNBC metastasis: cell-surface antigen CUB-domain containing protein 1 (CDCP1) and proteins in the lipid metabolism pathway. CDCP1 regulates lipid metabolism by reducing cytoplasmic lipid droplet abundance, stimulating fatty acid oxidation and oxidative phosphorylation. This metabolic pathway likely contributes to the energy production required for cell migration and metastasis of TNBC, and represents a potential therapeutic target.
Dysregulated lipid metabolism and FAO have recently been linked to breast cancer progression. Photoacoustic imaging of the mouse mammary tumor virus–polyoma middle T (MMTV-PyMT)-driven breast cancer model demonstrated that transformation of normal breast tissue to invasive carcinoma resulted in a progressive decrease of cytoplasmic LD abundance (29). In line with this finding, pharmacological activation of peroxisome proliferator-activated receptor-γ caused accumulation of LDs in breast cancer cells and decreased their proliferation (30). Furthermore, Src (31) and Myc (32) oncogenes were recently reported to contribute to lipid metabolism dysregulation in TNBC. Src kinase has been reported to stimulate FAO in a positive feedback loop, and pharmacological and genetic inhibition of FAO blocked TNBC metastasis in vivo (31). Myc has also been reported to stimulate FAO and pharmacological inhibition of FAO blocked tumor growth of Myc-driven TNBC tumors (32). These data indicate that lipid metabolism represents a potential therapeutic target in TNBC.

Lipid metabolism dysregulation has also been reported in other types of cancer. Pharmacological inhibition of Myc in neuroblastoma increased LD abundance, accompanied by growth arrest and apoptosis in vitro and increased animal survival in vivo (33). High-passage prostate cancer cells (comparable to metastatic cells) have lower LD abundance than their low-passage (comparable to primary tumor) counterparts (34). In a spontaneous mouse model of pancreatic cancer, the synthesis of acyl-CoA-modified lipids was found to be the most down-regulated metabolic pathway compared with normal pancreatic tissue (35). These data indicate that dysregulated lipid metabolism is characteristic of progression of multiple forms of cancer.

Here, we used coherent anti-Stokes Raman scattering (CARS) and two-photon excited fluorescence (TPEF) microscopy methods to assess TNBC metabolism. CARS microscopy detects the C-H bond in FAs, allowing quantification of the LD abundance (36). TPEF microscopy detects fluorescence from reduced NADH and oxidized flavin adenine dinucleotide (FAD). The relative ratio of the two fluorophores is defined as the optical redox ratio (ORR) (37), which we have previously correlated with the OxPhos rate (38). Previously, we found that CDCP1 is overactivated in TNBC compared with normal breast epithelial cells (14). Here we demonstrate that CDCP1 dysregulates lipid metabolism in TNBC by increasing gas chromatography and found that multiple long-chain (16 and 18 carbons) FAs had lower abundance in shScramble-transduced control cells compared with shCDCP1-transduced cells (SI Appendix, Fig. S2).

**Results**

**CDCP1 Lowers Intracellular LD Abundance in Breast Cancer Cells.** We have previously identified CDCP1 protein as a master-regulator of migration and invasion in TNBC (14). To get insight into the signaling pathways it regulates, we conducted mass spectrometric (MS) analysis of proteins interacting with CDCP1. We overexpressed CDCP1 with a C-terminal Flag-tag in HEK 293T cells and conducted coimmunoprecipitation (co-IP). Unexpectedly, we found that CDCP1 interacts with multiple proteins involved in metabolism based on PANTHER analysis (www.pantherdb.org) (SI Appendix, Fig. S1). Among these proteins was ACSL3, involved in lipid metabolism.

To assess CDCP1’s role in lipid metabolism, we first analyzed the effect of CDCP1 knockdown on LD abundance in three TNBC cell lines: MDA-MB-231, MDA-MB-468, and UCI-082014 (14), using two different shRNAs. We found that knocking down CDCP1 expression in all three cell lines increased LD content as analyzed by CARS microscopy (Fig. 1i). Second, we overexpressed CDCP1 in MDA-MB-231, MDA-MB-468, UCI-082014, and MCF7 cells and found that overexpression of CDCP1 decreased LD content of these cells (Fig. 1A). These results demonstrate that CDCP1 decreases LD abundance in breast cancer cells.

We further analyzed which lipid types were affected by CDCP1 expression in MDA-MB-231 and MDA-MB-468 cells using gas chromatography and found that multiple long-chain (16 and 18 carbons) FAs had lower abundance in shScramble-transduced control cells compared with shCDCP1-transduced cells (SI Appendix, Fig. S2).

**CDCP1 Expression Correlates with Breast Cancer Cell Invasiveness and Causes Appearance of Low-Lipid Broken Spheroids in 3D Culture.**

Because primary mammary epithelium cells (PME) were reported to have abundant LDs (30), we sought to compare their LD content to breast cancer cells. We found that PME and a nonmalignant breast cell line, MCF10A, had at least a twofold higher LD content than a panel of six breast cancer cell lines as analyzed by CARS microscopy (Fig. 2A, i and ii). Studies by others (5) and our group (14) have shown that CDCP1 cleavage leads to its activation to stimulate migration, invasion, and metastasis. Importantly, CDCP1 appears to be mostly full-length in PME and MCF10A and cleaved in five of five breast cancer cell lines that express CDCP1. Although CDCP1 is mostly full-length in SUM159 cells, the abundance of cleaved CDCP1 is still higher than in PME and MCF10A. Accordingly, all of the breast cancer cell lines formed irregular acini structures, spheroids, and patterns that have been linked to breast cancer progression.
In 3D culture and invaded the surrounding matrix compared with the normal hollow acini formed by PME and non-tumorigenic breast epithelial (MCF10A) cells in 2D culture. i) Representative 40× CARS images; ii) quantitation of CARS, statistics based on comparison with PME; iii) Western blot of CDCP1 expression. (B) Lower LD abundance correlates with invasiveness in 3D culture. i) Representative 40x CARS images of breast cancer cell lines in 3D culture; ii) quantitation of intact acini (PME and MCF10A), intact spheroids and broken spheroids (breast cancer cell lines). (C) CDCP1 overexpression in MCF7 cells promotes invasion observed as broken spheroids in 3D culture, which have lower LD content than intact spheroids. i) Representative 40x CARS images; ii) quantitation of the ratio of broken spheroids to total spheroids in VC- and CDCP1-transduced MCF7 cells; iii) quantitation of LD abundance in spheroids formed by VC- and CDCP1-transduced MCF7 and broken spheroids formed by CDCP1-transduced MCF7 cells, n = 3 in A, ii and C, iii. P values analyzed by one-way ANOVA with multiple comparison post hoc t test and error bars represent SEMs; *P < 0.05, **P < 0.01, ***P < 0.001 compared with VC; ****P < 0.0001 compared with CDCP1 spheroids.

**CDCP1 Interacts with ACSL Family Members Involved in Lipid Metabolism.** To investigate the molecular mechanism of the LD regulation by CDCP1, we decided to validate the interaction of CDCP1 with ACSL3 found by MS. CDCP1 and ACSL3 interact in HEK 293T cells overexpressing cCDCP1-Flag and ACSL3, as shown by co-IP (Fig. 3A). We further found that CDCP1 interacts with ACSL3 endogenously in MDA-MB-231 cells by proximity ligation assay (PLA) using shCDCP1-1 and shACSL3 as negative controls (Fig. 3B, i).

ACSL3 belongs to an ACSL protein family, including typical members 1, 3, 4, and 5 (26, 39). Thus, we conducted additional PLA assays and found that CDCP1 interacts with ACSL1, -3, -4, and -5 (Fig. 3B, ii and iii) (RhoC antibody was used as a negative control).

All ACSL antibodies and RhoC antibody used for PLA were verified to work for immunofluorescence (SI Appendix, Fig. S3).

**CDCP1 Regulates ACSL Activity.** The CDCP1/ACSL interaction suggested that CDCP1 is an ACSL regulator. We analyzed the CDCP1’s effect on ACSL activity using a previously established assay (40–43) based on mitochondria BODIPY labeled palmitate (structure in Fig. 4A). First, we validated the assay in TNBC cell lines treated with a pan-ACSL inhibitor, Triacsin C (Fig. 4B), and shACSL3-transduced TNBC cell lines (Fig. 4C). In both cases, we observed a decrease in ACSL activity compared with vehicle-treated cells and shScramble-transduced cells. Second, we analyzed ACSL activity in the same TNBC cell lines with manipulated CDCP1 expression. We found that ACSL activity was increased on average by 40% in shCDCP1-transduced cells compared with shScramble-transduced cells (Fig. 4D). Accordingly, ACSL activity was decreased on average by 15% in CDCP1 overexpressing cells compared with vector-control (VC) cells (Fig. 4E). CDCP1 expression was assessed by Western blot in Fig. 1A, ii and iii. These data suggest that CDCP1-mediated reduction of ACSL activity leads to decreased acyl-CoA production and storage in LDs.

**Low-Lipid Content Favors Promigratory Phenotype of Breast Cancer Cells.** We have shown that CDCP1 decreases cytoplasmic LD abundance and stimulates invasiveness in TNBC cells, and previously we have shown that CDCP1 stimulates TNBC cell migration (14). Our findings that CDCP1 interacts with ACSLs and negatively regulates their activity led us to investigate the effect of ACSL expression on migration. Consistent with the above data, we found that knocking down ACSL3 expression reduced LD abundance (Fig. 5A), increased TNBC cell migration (Fig. 5B) and invasion (SI Appendix, Fig. S4A), and lung metastasis of MDA-MB-231 cells injected into the mammary fat pad of Rag2−/− mice (SI Appendix, Fig. S4B). We further found that treatment of shCDCP1-transduced TNBC cells with pan-ACSL inhibitor, Triacsin C, reduced the LD abundance to the level of shScramble-transduced cells (Fig. 5C) and partially rescued the migration defects caused by CDCP1 knockdown (Fig. 5D and SI Appendix, Fig. S5). The data acquired with genetic (shACSL3) and pharmacologic (Triacsin C) inhibition of ACSL activity generated consistent results.
We previously demonstrated that CDCP1 cleavage and knockdown validation). CDCP1 regulates ACSL activity. (Fig. 4.) Validation of ACSL activity assay in TNBC cells. (A) Structure of BODIPY used for ACSL activity assays. (B and C) Western blot confirming ACSL3 knockdown; (D) CDCP1 knockdown increases ACSL activity in TNBC cells. (E) CDCP1 overexpression decreases ACSL activity in TNBC cells. P values analyzed by one-way ANOVA with multiple comparison post hoc t test and error bars represent SEMs; *P < 0.05, **P < 0.01, ***P < 0.001. Quantitation is the average of an n ≥ 3 for each panel. RFU, relative fluorescence units.

Interestingly, we observed distinct effects of ACSL3 and CDCP1 knockdowns on cell proliferation: ACSL3 knockdown decreased proliferation of MDA-MB-231, MDA-MB-468, and UCI-082014 cells (SI Appendix, Fig. S6A), whereas CDCP1 knockdown did not change proliferation (SI Appendix, Fig. S6B), consistent with previous reports for cell types other than TNBC (44, 45). Because CDCP1 is known to regulate multiple pathways in addition to ACSL (1, 5, 13, 14, 46, 47), it is likely that these override the effect of the CDCP1/ACSL axis on cell proliferation.

To further investigate the contribution of the ACSL pathway to CDCP1’s effect on LD abundance and invasion, we simultaneously transduced MDA-MB-231 and UCI-082014 cells with Triacsin C and found that OxPhos increased as decreasing LD abundance see Fig. S7 A, B. Upon culturing the cells in 3D, we found that the decrease in ORR and FAO in MDA-MB-231 cells by CDCP1 knockdown was rescued by Triacsin C treatment (SI Appendix, Fig. S8A). These data indicate that CDCP1 contributes to a low-lipid TNBC phenotype by increasing FAO and OxPhos and that ACSL inhibition by CDCP1 increases FAO and OxPhos. These data are in line with reports on CDCP1 (1–14), FAO (31), and OxPhos (50–52) promoting cell migration.

To further investigate the contribution of the ACSL pathway to CDCP1’s effect on LD abundance and invasion, we simultaneously knocked down ACSL3 and CDCP1 in MDA-MB-231 and UCI-082014 cells (see SI Appendix, Fig. S7A for knockdown validation) and conducted 3D assays (similar to Fig. 2). We found that the increase in LD abundance seen by knocking down CDCP1 was rescued by co-knockdown of ACSL3 in MDA-MB-231 and UCI-082014 cells (Fig. 5E and SI Appendix, Fig. S7B). Furthermore, we found that the decrease in ORR seen by knocking down CDCP1 was partially rescued by co-knockdown of ACSL3 (SI Appendix, Fig. S7C). Upon culturing the cells in 3D, we found that knocking down CDCP1 reduced invasiveness and growth of the cells [consistent with our previous findings (14)], and that co-knocking down ACSL3 rescued invasiveness of the cells and did not rescue the reduced growth (Fig. 5F). These data link inhibition of ACSL activity occurring downstream of CDCP1 to decreased LD abundance, and increased migration and invasion.

CDCP1 Increases FAO in Breast Cancer Cells. Interestingly, recent studies conducted in TNBC report two opposing disturbances in lipid metabolism: down-regulation of activators of lipid synthesis, along with up-regulation of activators of FAO (32, 33). We next sought to determine if the low-lipid phenotype caused by CDCP1 is a result of increased lipid utilization by FAO, in addition to decreased lipid activation for storage in LDs. First, we found that shCDCP1-transduced MDA-MB-231, MDA-MB-468, and UCI-082014 cells had lower levels of OxPhos than shScramble-transduced cells measured by ORR (SI Appendix, Fig. S8A). Second, to assess the contribution of FAO in OxPhos, we measured ORR after cell treatment with DMSO vehicle or FAO inhibitor EtoMoxir (48, 49). We found that the ∆ORR between DMSO- and EtoMoxir-treated cells was lower in shCDCP1-transduced than in shScramble-transduced cells (Fig. 6A), indicating that FAO rates decrease upon CDCP1 knockdown, lowering OxPhos dependent on the product of FAO. Third, to assess if the CDCP1/ACSL axis contributes to OxPhos, we treated TNBC cells with Triacsin C and found that OxPhos increased as measured by ORR (SI Appendix, Fig. S8B). We verified that Triacin C treatment increased FAO in TNBC cells (SI Appendix, Fig. S8C) using the same analysis as in Fig. 6 A, iii. Furthermore, we found that the decrease in ORR and FAO in MDA-MB-231 cells by CDCP1 knockdown was rescued by Triacsin C treatment (SI Appendix, Fig. S8A and D). Finally, treatment of TNBC cells with EtoMoxir to inhibit FAO increased LD abundance (SI Appendix, Fig. S9A) and reduced migration (SI Appendix, Fig. S9B) of TNBC cell lines, consistent with previous studies (31–33). These data indicate that CDCP1 contributes to a low-lipid TNBC phenotype by increasing FAO and OxPhos and that ACSL inhibition by CDCP1 increases FAO and OxPhos. These data are in line with reports on CDCP1 (1–14), FAO (31), and OxPhos (50–52) promoting cell migration.

We also assessed the differences in lipid transport to mitochondria between shScramble- and shCDCP1-transduced cells, as described in Rambold et al. (53). We pulsed TNBC cell lines with red C12 BODIPY (structure in SI Appendix, Fig. S10A) for 16 h and then co-stained with green MitoTracker to visualize mitochondria. Colocalization quantitated by Pearson’s coefficient of red (lipid) and green (mitochondria) staining indicated that CDCP1 knockdown reduced transport of lipsids into the mitochondria (Fig. 6B). We verified that mitochondrial mass did not differ in shScramble- and shCDCP1-transduced cells (SI Appendix, Fig. S10B).

Extracellular Portion of Cleaved CDCP1 Blocks CDCP1 Dimerization in Vivo, Which Is Accompanied by High LD Abundance and Reduced Metastasis. We previously demonstrated that CDCP1 cleavage and dimerization are important for driving TNBC migration and invasion (14). Moreover, we were able to block CDCP1 dimerization and activity by the expression of the secreted extracellular portion of cleaved CDCP1 (extracellular portion of cleaved CDCP1, ECC) (14). Thus, we hypothesized that in vivo ECC would block TNBC metastasis and increase the LD abundance in primary tumors. First, we found that LD abundance was higher in ECC-transduced UCI-082014 and MDA-MB-231 cells than in VC-transduced cells in vitro (SI Appendix, Fig. S1L4). Second, we implanted VC- or ECC-firefly luciferase-labeled UCI-082014 and MDA-MB-231 cells to fat pads of Rag2−/− mice. Five (UCI-081014) to 8 (MDA-MB-231) weeks after cell implantations, mice were imaged and then killed (Fig. 7A). We found that ECC inhibited the primary tumor growth in the UCI-082014-based model
Low-lipid content favors promigratory phenotype of TNBC. (A) ACSL3 knockdown reduces LD abundance in TNBC cell lines (i) representative 40× CARS images; (ii) quantitation of CARS. (B) ACSL3 knockdown increases migration of MDA-MB-231 and UCI-082014 (i) and MDA-MB-468 (ii) cells. (C and D) CDCP1 knockdown increases LD abundance (C) and reduces migration (D) in MDA-MB-231 (i), UCI-082014 (ii), and MDA-MB-468 (iii), and 5 μM Triacsin C treatment for 16 h (lowering lipids) partially rescues migration of shCDCP1-transduced cells. (E and F) Increase in LD abundance (E) and reduction in invasion (F) by CDCP1 knockdown can be rescued by co-knockdown of ACSL3. (E) Quantitation of LD abundance measured by Oil Red O (ORO) staining. (F) Quantitation of the ratio of broken/total spheroids in MDA-MB-231 (i) and UCI-082014 (ii) 3D cultures. (ii) Representative 20× phase-contrast images of 3D MDA-MB-231 and UCI-082014 cultures. *P < 0.05, **P < 0.01, ***P < 0.001 compared with respective vehicle-treated shScramble cells; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with respective vehicle-treated shACSL3 cells.

(Fig. 7 B, i). Although the same tendency was observed in the MDA-MB-231–based model (Fig. 7 B, ii), the data did not reach statistical significance (P = 0.0613). Furthermore, ECC inhibited metastasis to the lungs in both mouse models (Fig. 7 C). We verified that ECC was expressed by Western blot (SI Appendix, Fig. S11B) and inhibited CDCP1 dimerization as assessed by PLA in the primary tumors (Fig. 7 D and SI Appendix, Fig. S11C). As expected, we found that ECC increased the intracellular LD abundance in the primary tumors (Fig. 7 E and SI Appendix, Fig. S11D). Importantly, we also found that the lung metastases of the VC-transduced cells had lower LD abundance than their corresponding primary tumors (Fig. 7 F), providing further support to the low-lipid phenotype supporting metastasis. Finally, we found that ACSL activity was higher in ECC-expressing UCI-082014 and MDA-MB-231 tumors compared with VC control tumors (Fig. 7 G).

In summary, our data indicate that CDCP1 promotes TNBC metastasis by reducing LD abundance, promoting lipid accumulation in the mitochondria for FAO to fuel OxPhos, and promoting cell migration. CDCP1 regulates those processes, in part, by suppressing ACSL activity. As a result, TNBC tumors have a low-lipid phenotype.
Discussion

CDCP1 function-blocking antibodies have demonstrated effectiveness at inhibiting tumor growth (54) and metastasis (5) in vivo. We have previously shown that the CDCP1 function-blocking fragment, ECC, inhibits CDCP1 dimerization and activation in vitro (14) and here show its efficacy in vivo in two animal models of TNBC. Our data support targeting CDCP1 in TNBC to block metastasis and provide insight into the mechanism of CDCP1-induced metastasis. We demonstrate that CDCP1 regulates lipid metabolism, reducing LD abundance and stimulating FAO. Products of FAO, in turn, stimulate OxPhos, which contributes to TNBC migration and metastasis. Our data also show that the CDCP1/ACSL axis contributes to dysregulated lipid metabolism.

Importantly, the contributions of FAO (31, 32) and OxPhos (50) to TNBC migration and metastasis and OxPhos to metastasis of other cancers (55, 56) have been recently documented, supporting our proposed mechanism. Accordingly, pharmacological and genetic inhibitors of carnitine palmitoyltransferases blocked lipid transport to mitochondria, FAO, OxPhos, and metastasis of TNBC cells (31, 32). Recently, Myc overexpression has been shown to drive FAO in TNBC (32, 33). All of the cancer cell lines used in this study overexpress Myc compared with MCF10A cells (SI Appendix, Fig. S12). Importantly, MCF7 cells, which do not express endogenous CDCP1, overexpress Myc, which might explain their CDCP1-independent low-lipid phenotype (Fig. 2). Because both Myc and CDCP1 are overexpressed in TNBC cell lines used in this report, it is worth investigating if Myc and CDCP1 pathways contribute to TNBC lipid metabolism independently or if there is cross-talk. Interestingly, several studies have shown that proteins involved in the CDCP1 pathway, Src (47) and PKCδ (1), are involved in lipid metabolism as well. FAO and OxPhos activate Src, which in turn induces OxPhos in TNBC (31), and OxPhos activates PKCδ (57). Taken together, these data suggest that targeting lipid metabolism in general, and CDCP1 in particular, are viable therapeutic strategies to inhibit FAO, OxPhos, and metastasis of TNBC.

In this study, we suggest that, through FAO and subsequent OxPhos, lipids provide energy contributing to migration and metastasis. However, although the NADH and FADH2 of FAO are generally shuttled into OxPhos, the acetyl-CoA produced from FAO can enter many different pathways, including the tricarboxylic acid cycle, which feeds into OxPhos, posttranslational modifications, and biosynthetic pathways. In addition, we envision other mechanisms linking lipid metabolism to migration and metastasis. For example, LDs appear to be not merely inert structures for lipid storage, but dynamic signaling organelles (58, 59). The literature supports the cross-talk between cellular LDs and membrane lipid rafts (60–62), where multiple proteins involved in migration, including integrins (63, 64) and CDCP1 (54, 65), reside. On the other hand, the biophysical properties of high-lipid vs. low-lipid cells remain unknown and await investigation. Thus, our study opens an intriguing research direction into dissecting the mechanism of LD contribution to cancer cell migration and metastasis,
Fig. 7. Expression of a CDCP1-blocking fragment, ECC, increases LD abundance and reduces metastasis. (A) Representative images of mice with luciferase-labeled UCI-082014 (i) or MDA-MB-231 (ii) tumors at week 5 and 8 posttumor implantation, respectively. *VC-5 killed 2 wk early because of extensive disease progression and visibly reduced quality of life. (B) ECC reduces primary (1°) tumor growth of UCI-082014 (i) and trends toward reducing 1° tumor growth of MDA-MB-231 (ii) cells implanted into the fat pad of Rag2−/− mice. (C) ECC expression reduces lung metastasis of UCI-082014 and MDA-MB-231 tumors. (i and ii) Representative 4× images of H&E-stained lungs from mice implanted with UCI-082014 (i), metastases are shown by arrowheads, and MDA-MB-231 (ii) cells. (iii and iv) Quantitation of UCI-082014 (iii) and MDA-MB-231 (iv) metastasis. (D) ECC reduces CDCP1 dimer formation in 1° tumors as assessed by PLA. Representative 20× images (i) and quantitation (ii) of PLA. (E) ECC increases LD abundance in 1° tumors. Representative 20× images (i) and quantitation (ii) of Oil Red O (ORO) staining. (F) VC-transduced 1° tumors have higher LD abundance than the corresponding metastatic nodules. Representative 20× images (i) and quantitation (ii) of ORO staining. (G) ECC stimulates ACSL activity in 1° tumors. Quantitation of ACSL activity in VC- and ECC-transduced UCI-082014 and MDA-MB-231 primary tumor tissue. Each point represents an individual tumor. P values (as indicated) analyzed by one-way ANOVA with multiple comparison post hoc t test and error bars represent SEMs. A.U., arbitrary units.
which will be instrumental in revealing new pathways for thera-
peutic targeting of TNBC.

Here we show that CDCP1 promotes FAO in normoxia. Our ob-
servations put CDCP1 at the crossroads of metabolic path-
ways, as we (1, 14) and others (2) have previously shown that
CDCP1 activity increases under hypoxia, recognized to favor the
metabolic shift from OxPhos to glycolysis (66). CDCP1 activity
increases through its cleavage and phosphorylation, likely through
activation of Src kinase (2). Because most TNBC tumors have
multiple hypoxic areas (67), it raises the question of regional
CDCP1 activation status and coordination of FAO/OxPhos and
glycolysis. Further investigation is needed to establish the role of
CDCP1 in FAO under a range of oxygen tensions and the role of
lipids supplied by the microenvironment vs. being endogenously
synthesized.

In this study, we concentrated on CDCP1-driven TNBC me-
tastasis, and it is worth investigating whether our data translate
to other types of breast cancer. The only non-TNBC cell line
used in this study was MCF7, which is ER⁺, and although
CDCP1 overexpression leads to increased invasiveness in 3D and
decreased LD abundance, these cells do not endogenously ex-
press CDCP1. It is important to keep in mind that the role of
CDCP1 in HER2⁺ breast cancer was addressed just on the level of
primary tumor growth, not metastasis, generating controversial
results. Homozygous germine CDCP1 knockout in MMTV-
PyMT spontaneous mouse model lead to increased tumor growth
rate (68). However, in a BT474-based mouse model, CDCP1
overexpression led to increased tumor growth (44). Furthermore,
high coexpression of CDCP1 and HER2 was correlated with de-
creased patient survival (44). It will be important to investigate
the regulation of lipid metabolism by CDCP1 across breast cancer
subtypes.

In this study, we used two animal models of TNBC. Whereas
ECC reduced primary tumor growth in a UCI-082014–based
animal model, it only trended toward reducing primary tumor
growth in a MDA-MB-231–based model. However, in both
models ECC reduced metastasis. Although both MDA-MB-231
and UCI-082014 are triple-negative, they have different genetic
backgrounds, which likely contribute to the degree of their de-
pendency on the CDCP1 pathway for tumor growth. In this re-
spect, we recently established UCI-082014 from a primary tumor
specimen and MDA-MB-231 from a metastatic site. In the current
design of this study, we chose two breast cancer cell lines, which
micrometastasize to the lungs; MDA-MB-231 cell im-
plantations generate large primary tumors, whereas MDA-MB-231
harbor mutations in BRAF and KRAS, and UCI-082014 cell im-
plantations; MDA-MB-231 harbor mutations in BRAF and KRAS.

Because CDCP1 represents a potential therapeutic target, it will be important to determine the
genetic and epigenetic factors informing on the effect of CDCP1
blockage on the primary tumor growth. Accordingly, ECC-based
therapeutic could be potentially used in a neo-adjuvant or
adjuvant setting.

To date, the ACSL activity was predominantly studied in the liver,
where it does not affect FAO. This finding is highlighted by a study
that found that the pan-ACSL inhibitor, Triacsin C, preferentially
inhibited TAG synthesis and did not affect FAO (71). Furthermore,
although both ACSL1 and ACSL5 have been reported to localize
to the mitochondrial and the LD membranes (72) and ACSL1 has
been reported to up-regulate genes involved in FAO (73), they do
not affect the FAO rate (74, 75). Based on our data, ACSLs pro-
mote lipid storage in LDs (Fig. 5A and SI Appendix, Fig. S7B), in-
hibit OxPhos (SI Appendix, Fig. S7C), and inhibit FAO (SI Appendix,
Fig. S8C) in TNBC. Considering that ACSL products, acyl-CoAs,
are competed for by enzymes involved in LD storage, incorporation
into lipid membranes, posttranslational modifications, and FAO (25,
76), our data that ACSL activity inhibits FAO are consistent with
a choice to direct acyl-CoAs toward storage in LDs. Accordingly,
when ACSL activity is blocked, acyl-CoAs become limited and may
preferentially enter FAO, and when ACSL activity is induced, acyl-
CoAs become abundant and may preferentially enter LDs for
storage. Additional studies are needed to investigate the regulatory
mechanism, as well as the cell-type-specific roles of ACSLs in lipid
metabolism. Because CDCP1 has a large effect on LD abundance
and a modest effect on ACSL activity, we expect that CDCP1 in-
teracts with and regulates additional metabolic proteins that are yet
to be uncovered.

Interestingly, ACSL3 was recently reported to promote lung
cancer growth in a KRASG12D–driven mouse model, although its
contribution to metastasis was not investigated (77). Our in vitro
data show that ACSL3 increases TNBC cell proliferation and at
the same time decreases TNBC migration (Fig. 5 and SI Appendix,
Fig. S6). Our in vivo data show that ACSL3 reduces metastasis
(SI Appendix, Fig. S4).

The observation that VC-transduced UCI-082014 generated
metastases with lower LD abundance than the corresponding
primary tumors suggests that cells in primary tumors with low LD
abundance effectively migrate and metastasize and keep the low
LD abundance phenotype at metastatic sites. Importantly, this
finding raises the question of TNBC tumor heterogeneity in
terms of CDCP1 expression and activity, as well as CDCP1-
dependent and -independent regulation of LD abundance. Thus,
the frequency of cells with high CDCP1 activity and low LD abun-
dance in primary tumors might represent a prognostic marker
for metastatic potential. This observation also implies that the aver-
age CDCP1 expression and activity should be higher at metastatic
sites than in corresponding primary tumors. Accordingly, Alajati
et al. (44) reported that CDCP1 expression is higher in HER2⁺
patient breast cancer metastases than the primary tumors. It is
important to note that although our data support the mechanism
where low LD abundance stems from CDCP1 overexpression and
lipid FAO, thus depleting LDs, the dynamics of lipid metabolism
in TNBC tumor tissue is largely unknown. The low LD abundance
phenotype can arise from low-lipid synthesis and high-lipid con-
sumption. In both cases the amount of lipids detected in the tumor
tissue will decrease. Adding to complexity are the additional cell
types present in the tumor microenvironment, including adipo-
cytes, potentially capable of supplying lipids to breast cancer cells
for FAO. Supporting the importance of lipid FAO for metastasis
are the results from Park et al. (31), which show that Etomoxir,
blocking mitochondrial lipid consumption, does block metas-
tasis. Further studies are needed to clarify those important
considerations.

In conclusion, our data establish CDCP1 as a master-regulator
of lipid metabolism in TNBC, lowering LD abundance and in-
creasing FAO, leading to a low-lipid phenotype of TNBC. This
signaling pathway is partially regulated by the CDCP1/ACSL axis.
Because of the interconnection of metabolic pathways, increased
FAO leads to increased OxPhos, contributing to migration and
metastasis. As a result, CDCP1 represents a potential therapeutic
target for TNBC management, along with other components of the
lipid metabolism pathway. Thus, our findings have important im-
lications for therapeutic targeting and development of prognostic
markers of TNBC.

Materials and Methods
CARS Microscopy. A 76-MHz mode-locked Nd:vanadate laser provides a beam at
1,064 nm functioning as the Stokes beam and a second harmonic generated beam at
532 nm to pump an optical parametric oscillator. The pump beam generated by
the optical parametric oscillator is spatially and temporally overlapped with the
Stokes beam and sent to the microscope. The two beams are focused on the cells
through a 60×, 1.2 numerical aperture water objective lens. The generated CARS
signals are collected through the condenser and focused onto a Hamamatsu
photomultiplier tube with a 650 ± 50-nm bandpass filter in front.

Wright et al.

PNAS | Published online July 24, 2017 | E6653

PNAS PLUS

CELL BIOLOGY

SI Appendix

www.pnas.org/cgi/doi/10.1073/pnas.1705235114

Copyright © 2017 The Authors.

Published by the National Academy of Sciences.
A scanning laser TPEF microscope was used to measure the metabolic states of the cell lines. The laser was set to 740 nm to excite NADH (480 ± 50-nm bandpass filter) and to 820 nm to excite FAD (515 ± 50-nm bandpass filter). We used 20 mW for 740 nm and 40 mW for 900 nm with a 6-μs pixel dwell time. The laser power was kept constant and the response of the photo multiplier tubes was calibrated with a reference sample (0.02 μM fluorescein solution at pH 7.0). The images of NADH and FAD + were of the same cells were taken sequentially and were used to calculate ORR, defined as (FAD + /NADH + FAD) × 100%.

FAO Analysis. Two dishes for each experimental group were prepared. On each imaging dish, 80,000 cancer cells were plated and cultured in full-growth medium (DMEM, 10% FBS, 25 mM glucose, 2 mM Glutamax, 1% penicillin/streptomycin) for 24 h to allow cell attachment. The growth medium was exchanged to substrate-limited medium (DMEM, 0.5 mM glucose, 1 mM Glutamax, 0.5 mM carntine, and 1% FBS) a day before the experiment. The cancer cells were switched to basal FAO medium (DMEM, 2.5 mM glucose, 0.5 mM carntine, and 5 mM Hepes) 45 min before the experiment. Etoperox was added to the medium 15 min before the experiment at a final concentration of 40 μM. In each imaging dish, three locations were randomly chosen. The baseline ORRs were measured at time 0 before Oligo addition. The optical redox changes were monitored every 5 min for a total of two measurements. Then, 5 μL of FCCP was added and the ORRs were measured at 15 min and 20 min. Images were taken using TPEF Microscopy (see above).

All ORR measurements were done in the absence of exogenous lipid sources.

Virus Production and Infection of Target Cells. Detailed protocol is described in Razorenova et al. (78). HEK 293T cells were transfected with each lentiviral plasmid along with packaging plasmids, pVSVG and ΔR8.2. Virus-containing media were targeted to target TNBC cells, which were selected in antibiotic-containing media for a minimum of 1 wk.

Western Blotting. The Western blotting protocol was adapted from Razorenova et al. (79). Forty micrograms of protein were used per lane. Antibodies used are listed in SI Appendix, Table S1.

Western Blotting.

Scratch Assays. A detailed protocol of scratch assays is described in Wright et al. (14). For scratch assays, 400,000 MDA-MB-231 or UCI-082014 cells were plated on a well of a six-well plate. Twenty-four hours later, cells were treated with DMSO control or 5 μM Triacsin C for 16 h before assay. Cells were allowed to migrate for 6 h.

Transwell Migration. A detailed protocol of assay and quantitation is described in Thompson et al. (80). MDA-MB-468 cells were treated with DMSO control or 5 μM Triacsin C for 16 h before assay. Cells were allowed to migrate for 16 h.

In Vivo Experiments. All animal research in this study was approved by the Institutional Animal Care and Use Committee of the University of California, Irvine. UCI-082014 and MDA-MB-231 cells were transduced with VC or pLMI-CMV-ECC-His (14). Rag2−/− mice were orthotopically injected in the fourth mammary fat pad with 10^6 cells mixed with Matrigel. Before being killed at 5 wk for the UCI-082014–based model and at 8 wk for the MDA-MB-231–based model, mice were intraperitoneally injected with 150 mg/kg o-lucin and imaged for 2 min on a live-animal imaging scanner. Mice were then killed, and tumors and lungs were collected for analysis. UCI-082014 metastases were quantitated as the average number of metastases per field in three to five images taken from three nonserial sections per lung per mouse. MDA-MB-231 metastases were quantitated as the total area of metastases per field because of the metastatic burden being too large to quantify individual metastases. Quantitation of Oil Red O staining was done using imageJ to quantify the number of lipid droplets per cell. Quantitation of the PLA assay was done by manually counting the number of lipid droplets.

All other material and methods can be found in SI Appendix, Supplemental Material and Methods.

ACKNOWLEDGMENTS. We thank Dr. Kaiser for MDA-MB-231 and MDA-MB-468 cell lines; Dr. Wang for SUM159 and BT549 cell lines; Dr. Dai for MCF10A cell line; Dr. Verma for pVSVG and ΔR8.2 lentivirus packaging plasmids; Dr. Binkley for the pCMV-GWCMV lentivector; Dr. Bokio for Rag2−/− mice; Jeffrey Kim at the University of California, Irvine Pathology for Oil Red O staining; Dr. Ghassian at the University of California, San Diego Biomolecular and Proteomics Mass Spectrometry Facility for analysis of CDCP1–binding partners; Carla Harris and Dr. Swift at the Vanderbilt Hormone Assay & Analytical Services Core for gas chromatography quantitative analysis of intracellular lipid types; and Dr. Fan for critical reading of the manuscript. This work was supported by Concern Foundation Award CF-204722 (to O.V.R.); National Cancer Institute Grant R01CA142989 (to B.J.T.); National Institute of Biomedical Imaging and Bioengineering Grant P41EB013890 (to B.J.T.); an Arnold and Mabel Beckman Foundation award (to B.J.T.); and National Cancer Institute Grant F31CA196226 (to H.W.).


